Heres why this move deserves attention Big Bet on a Blockbuster Segment Entry into the fast-growing GLP-1 (semaglutide) space Taps into a market set to explode with rising diabetes & obesity cases Timed perfectly post patent expiry early-mover advantage Product That Matches Global Standards Once-weekly injectable better patient adherence Available in 2 mg & 4 mg pre-filled pens Backed by Phase III data comparable efficacy + strong safety Premium Generic Strategy (Not a Price WarYet) Priced at ~4,200/month Positioned as a trusted, high-quality branded generic Targets urban, quality-conscious patients over deep discounting Full-Stack Manufacturing Power API + formulation + delivery device all in-house Strong edge in complex peptides & scale-up capability Sets the stage for global expansion Beyond Drug: Building a Patient Ecosystem SemaKare support program Focus on adherence, education & outcomes Shift from product-selling solution-building Competitive Storm Incoming Multiple Indian pharma giants entering semaglutide Likely outcomes: Price erosion Wider access Massive market expansion The Real Play

In indirect comparisons, oral semaglutide at 25 mg produced roughly 14% weight loss, while Rybelsus at 14 mg has been associated with approximately 5% weight loss in diabetes trials
If youve experienced vision loss while taking Ozempic or similar medications, its crucial to understand what the evidence says and what your legal options might be
It can be kept at room temperature, up to 86F (30C), for up to 21 days
The side effect profile looks similar to other GLP-1 drugs, with nausea being the most common complaint